Clinical Trials Logo

Clinical Trial Summary

This phase IV trial studies how well influenza vaccination works in preventing infections such as influenza in patients with plasma cell disorders. Influenza infections may theoretically support the growth of tumor cells and improving protection against influenza may improve the status of patients' plasma cell disorder. Giving influenza vaccination may reduce influenza-related complications including infections, hospitalizations, and deaths, and improve the status of plasma cell disorders.


Clinical Trial Description

PRIMARY OBJECTIVES: I. Demonstrate an absolute 25% increase in seroprotection, defined as hemagglutination antibody inhibition (HAI) > 40 against all strains, at week 21 in the experimental arm compared to the control arm. II. Determine correlation between HAI, predefined risk of influenza-like illness (low, moderate, high), and progression-free survival (PFS). EXPLORATORY OBJECTIVES: I. Measurement of B & T-cell subsets and flu-specific responses as a way of understanding immunosuppression in this patient population, correlating with influenza-like illness. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients receive trivalent influenza vaccine intramuscularly (IM) at weeks 1, 9, and 17, and pneumococcal 13-valent conjugate vaccine IM at week 5 in the absence of disease progression or unacceptable toxicity. ARM II: Patients receive trivalent influenza vaccine IM at week 1 and pneumococcal 13-valent conjugate vaccine IM at week 5 in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed for 4 weeks and then periodically for 2 years. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04080531
Study type Interventional
Source Emory University
Contact
Status Completed
Phase Phase 4
Start date October 18, 2019
Completion date December 15, 2022

See also
  Status Clinical Trial Phase
Completed NCT00729118 - Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma Phase 1
Completed NCT00400686 - Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma N/A
Completed NCT01219010 - A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma Phase 1
Completed NCT00547365 - Human Immune Globulin in Treating Patients With Primary Amyloidosis That is Causing Heart Dysfunction Phase 1/Phase 2
Completed NCT00064038 - S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma Phase 3
Completed NCT00028600 - Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma Phase 2
Recruiting NCT05336383 - Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma Phase 2
Withdrawn NCT01558778 - Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant N/A
Recruiting NCT04354246 - COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies Phase 1
Terminated NCT00303719 - Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy Phase 2
Completed NCT00536601 - High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors N/A
Completed NCT00005792 - Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma Phase 1
Completed NCT00602693 - T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer Phase 1
Completed NCT00118339 - Ice Chips or Saline Mouth Rinse in Reducing or Preventing Mucositis in Patients Receiving Melphalan and Autologous Stem Cell Transplant for Multiple Myeloma N/A
Terminated NCT00790842 - Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction Phase 1/Phase 2
Completed NCT01484015 - Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia Phase 1
Completed NCT02556931 - Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies Phase 2
Completed NCT00874211 - S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Completed NCT01132833 - Biomarkers Related to Thrombosis in Patients With Newly Diagnosed Multiple Myeloma Receiving Chemotherapy Phase 1
Completed NCT00053196 - Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer Phase 2